Keywords: AGI Therapeutics, Axcan Pharma, omeprazole, gastroentorolgy

AGI Thera terminates omeprazole deal with Axcan

Article | 14 August 2009

• Print This

Irish drugmaker AGI Therapeutics says that its co-development/co-fund and licensing agreement for AGI-010 with the USA’s Axcan Pharma privately-held, specialty pharmaceutical company in the field of gastroenterology, has been terminated by mutual agreement.  AGI-010 is the company’s bimodal modified release once-daily formulation of the proton pump inhibitor drug omeprazole for the treatment of gastroesophageal reflux disorder (GERD).  AGI now regains full control of AGI-010 and neither party has any outstanding or future obligations to the other. 

AGI and Axcan entered into a co-development/co-fund and license agreement in September 2006 to jointly develop AGI-010 for North American markets and the parties have worked together since then to develop and optimize the formulation and conduct human clinical testing. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.